Blood test detects Alzheimer's with 94.5% accuracy, offering non-invasive alternative

Alzheimer's affects 57 million people worldwide with projections reaching 139 million by 2050, creating substantial burden on healthcare systems and families.

For decades, the shadow of Alzheimer's disease has fallen slowly and often invisibly, leaving patients and physicians to navigate uncertainty with blunt and burdensome tools. Now, a protein called p-tau217, measurable in a simple blood draw, is offering something medicine has long sought: a way to see the disease before it fully arrives. Two independent bodies of research, published within days of each other in early 2026, converge on the same conclusion — that this biomarker can identify Alzheimer's with 94.5% accuracy, changing diagnoses in one of every four patients examined. In a world whe

Blood test detects Alzheimer's with 94.5% accuracy, offering non-invasive alternative

Cobertura Relacionada

Receba o Register no seu e-mail